{
  "company": {
    "name": "Nucleix",
    "website": "https://nucleix.com/",
    "record": "https://startuphistory.org/c/nucleix.com"
  },
  "status": null,
  "history_since": "2016-07-30T00:46:26.000Z",
  "baseline": {
    "snapshot_id": "3aef8f7f68c07abc969d39c6750addd616ee741c52869c5595e36ffea921ea2e",
    "observed_at": "2016-07-30T00:46:26.000Z",
    "headline": "Using Epigenetics for Cancer Detection in Liquid Biopsy | Nucleix",
    "description": "EpiCheck is a highly innovative product for detection of cancer in liquid biopsy samples, using a panel of various methylation biomarkers",
    "evidence": "https://web.archive.org/web/20160730004626/http://nucleix.com:80/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-06T17:51:04.010Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2022-08-16T00:23:40.000Z",
      "variants": [
        {
          "headline": "Using Epigenetics for Cancer Detection in Liquid Biopsy | Nucleix",
          "subhead": "EpiCheck is a highly innovative product for detection of cancer in liquid biopsy samples, using a panel of various methylation biomarkers",
          "observed_at": "2016-07-30T00:46:26.000Z",
          "evidence": "https://web.archive.org/web/20160730004626/http://nucleix.com:80/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Using Epigenetics for Cancer Detection in Liquid Biopsy | Nucleix",
          "subhead": "EpiCheck is a highly innovative product for detection of cancer in liquid biopsy samples, using a panel of various methylation biomarkers",
          "observed_at": "2018-02-11T05:40:04.000Z",
          "evidence": "https://web.archive.org/web/20180211054004/http://nucleix.com:80/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Using Epigenetics for Cancer Detection in Liquid Biopsy | Nucleix",
          "subhead": "EpiCheck is a highly innovative product for detection of cancer in liquid biopsy samples, using a panel of various methylation biomarkers",
          "observed_at": "2020-06-16T07:42:36.000Z",
          "evidence": "https://web.archive.org/web/20200616074236/https://nucleix.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Using Epigenetics for Cancer Detection in Liquid Biopsy | Nucleix",
          "subhead": "EpiCheck is a highly innovative product for detection of cancer in liquid biopsy samples, using a panel of various methylation biomarkers",
          "observed_at": "2021-01-20T04:31:01.000Z",
          "evidence": "https://web.archive.org/web/20210120043101/https://nucleix.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Using Epigenetics for Cancer Detection in Liquid Biopsy | Nucleix",
          "subhead": "EpiCheck is a highly innovative product for detection of cancer in liquid biopsy samples, using a panel of various methylation biomarkers",
          "observed_at": "2022-08-16T00:23:40.000Z",
          "evidence": "https://web.archive.org/web/20220816002340/https://nucleix.com",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Using Epigenetics for Cancer Detection in Liquid Biopsy | Nucleix",
      "subhead": "EpiCheck is a highly innovative product for detection of cancer in liquid biopsy samples, using a panel of various methylation biomarkers",
      "from": "2016-07-30T00:46:26.000Z",
      "to": "2022-08-16T00:23:40.000Z",
      "captures": 5,
      "evidence": "https://web.archive.org/web/20220816002340/https://nucleix.com",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2016-07-30T00:46:26.000Z",
          "to": "2022-08-16T00:23:40.000Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-98aef21737f6a6005567c5f0d8e486f894b0d72a0fea26e18be43ae16bea081c:9ba5c8fde511ba9796c2b7ba2d8db7b99aeef99abbd30b7db36c9a0da9c1b649:logos:8332e6f803c74541",
      "before_evidence": "https://web.archive.org/web/20200616074236/https://nucleix.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "logos",
      "label": "New logos",
      "summary": "Added logos to its homepage: Untitled2 and Untitled3.",
      "between": {
        "from": "2020-06-16T07:42:36.000Z",
        "to": "2021-01-20T04:31:01.000Z"
      },
      "evidence": "https://web.archive.org/web/20210120043101/https://nucleix.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 2,
      "id": "page-f79ea5905b864be0e235837c1b6d7c28c6bb042a2008f98d456edb87c7e7f086:00c0890ce7489a8445228564a1521deaa471b05c444a6fabbd10a05470e1234b:compliance:32e4bbc0ca728b62",
      "before_evidence": "https://web.archive.org/web/20220816002340/https://nucleix.com",
      "before_evidence_kind": "internet_archive",
      "kind": "compliance",
      "label": "Compliance",
      "summary": "Now states CE-MARKED compliance on its homepage.",
      "between": {
        "from": "2022-08-16T00:23:40.000Z",
        "to": "2024-01-29T02:54:06.000Z"
      },
      "evidence": "https://web.archive.org/web/20240129025406/https://nucleix.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-compliance"
    }
  ],
  "update": {
    "headline": "Nucleix adds logos and states CE-MARKED compliance",
    "summary": "Nucleix added new logos to its homepage and later started stating CE-MARKED compliance on its homepage. These site updates may reflect positioning of its offerings in regulated markets.",
    "points": [
      {
        "text": "Between June 2020 and January 2021, Nucleix added logos to its homepage: Untitled2 and Untitled3.",
        "kind": "fact",
        "changes": [
          1
        ]
      },
      {
        "text": "Between August 2022 and January 2024, Nucleix started stating CE-MARKED compliance on its homepage.",
        "kind": "fact",
        "changes": [
          2
        ]
      },
      {
        "text": "The statement of CE-MARKED compliance on the homepage between August 2022 and January 2024 suggests Nucleix may be emphasizing regulatory status in its public positioning.",
        "kind": "interpretation",
        "changes": [
          2
        ]
      }
    ],
    "written_at": "2026-11-07T15:27:54.772Z",
    "basis": "ai_analysis",
    "model": "gpt-5.1-2025-11-13"
  },
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Nucleix” company record, https://startuphistory.org/c/nucleix.com"
}